PhenoPath at USCAP 2007 Annual Meeting

PhenoPath Laboratories actively participated in the 2007 Annual Meeting of the United States and Canadian Academy of Pathology in San Diego, CA from March 24 – 30, 2007. Our pathologists gave multiple talks in addition to presenting several abstracts highlighting our ongoing clinical research studies, as detailed below. PhenoPath also exhibited at the meeting from March 26 – 28, showcasing new immunohistochemistry and molecular tests, along with our 9-color flow cytometry services.

Saturday, March 24, 2007

7:00-10:00 PM: Allen M. Gown, MD of PhenoPath Laboratories is presenting at the CAP Companion Society Education Program Meeting, Best Practices in Contemporary Diagnostic Immunohistochemistry. Dr. Gown’s talk is entitled, "Best Practice Panels for Carcinoma of Unknown Primary"

Monday, March 26, 2007

AM: Poster Presentation #34: AB Rajpug, MC Cheang, DK Voduc, DA Turbin, S Leung, KA Gelmon, AM Gown, BC Gilks, DG Huntsman. "Evaluation of Hormone Receptor Status in Breast Cancer Using New Progesterone Receptor Antibody."

AM: Poster Presentation #116: D Westfall, AL Folpe, GP Paner, E Oliva, LC Goldstein, AM Gown, MB Amin. "Utility of a Comprehensive Immunohistochemical (IHC) Panel in the Differential Diagnosis of Spindle Cell Lesions of the Urinary Bladder."

AM: Poster Presentation #122: I Chebib, DN Ionescu, A Alkushi, AM Gown, GB Gilks. "Immunohistochemical Comparison of Endometrioid Carcinomas of Ovary Versus Endometrium."

8:15 AM: Platform Presentation, Session C (CC 1 A/B): D Cao, AM Gown, RS Vang, RJ Kurman, BM Ronnett. "Expression of PAX2 in Endometrial Hyperplasia and Carcinomas: Immunohistochemical Analysis of 136 Cases ."

8:45 AM: Abstract #128 Platform Presentation, Session D (CC 5 A/B): LC Goldstein, SE Tirrell, TS Barry, SJ Kussick, PL Kandalaft, PM Kim, AM Gown. "Immunophenotypic Profile of the Basal-like Subtype of Invasive Breast Carcinomas: Influence on Diagnosis and Therapy." Presented by Patricia Kim, MD.

PM: Poster Presentation #57: J Dahl, JK Greenson, GT Furuta, TS Barry, JL Hornick, RD Odze. "Distinct Subtypes of Dendritic Cells, T- and B-Lymphocytes in Primary Eosinophilic Esophagitis: Implications Regarding Pathogenesis and Differential Diagnosis with GERD."

PM: Poster Presentation #132: DN Ionescu, I Chebib, A Alkushi, AM Gown, CB Gilks. "Immunohistochemical Comparison of Serous Carcinomas of Ovary Versus Endometrium."

1:00 PM: Abstract #154 Platform Presentation, Session D (CC 5 A/B): PM Kim, LC Goldstein, TS Barry, SJ Kussick, PL Kandalaft, AM Gown. "Extremely High Concordance Between Immunohistochemistry and FISH Testing for HER2 Status Using Subtraction Methodology Scoring in Breast Cancer: a Study of 5942 Cases." Presented by Allen M. Gown, MD.

Tuesday, March 27, 2007

11:15 AM: Abstract #864 Platform Presentation, Session B (CC 6 C/F): TS Barry, PM Kim, DO Treaba, SE Tirrell, SJ Kussick, CH Tse, PL Kandalaft, AM Gown. "Use of p57KIP2 and Ki-67 Immunohistochemistry and Interphase FISH in the Diagnosis of Hydatidiform Mole: A Unique Algorithmic Approach." Presented by Todd S. Barry, MD, PhD.

11:15 AM: Platform Presentation, Session A: E Oliva, DS Kaufman, WU Shipley, B Spicer, GP Paner, AM Gown, MB Amin. "Immunohistochemistry as an Adjunct in the Differential DIagnosis of Radioation-Induced Atypia vs Carcinoma In Situ (CIS) of the Bladder. A Study of 48 Cases."

12:00-1:00 PM (Location: Edward B/C/D): Angelo Paolo Dei Tos, MD of Hospital of Treviso, Italy and Allen M. Gown, MD, of PhenoPath Laboratories present at an Educational Event sponsored by Lab Vision – Thermo Fisher Scientific. Dr. Gown’s talk is entitled, "IHC Markers in Breast Cancer: Methodology Matters."

Wednesday, March 28, 2007

8:00 AM to 5:30 PM: Marc Ladanyi, MD of Memorial Sloan-Kettering Cancer Center, New York and Allen M. Gown, MD of PhenoPath Laboratories are Co-Directors of the Long Course, Targeted Therapy of Cancer: New Roles for Pathologists. This course focuses on how targeted therapies of cancer are impacting the practice of surgical pathology. Each talk provides an overview of the biology behind the specific targeted therapies, indications for their use, their clinical impact, the eligibility criteria (as defined by histology, or by detection of the target by IHC or molecular assays), specimen requirements and how testing is performed, histologic aspects of response assessment, molecular monitoring of disease, and biologic and histopathologic aspects of secondary resistance, as relevant for each cancer setting. Dr. Gown is a featured speaker and will present:

• An overview of the current status of ER/PR determination and hormonal therapy
• Summary of HER2 biology and clinical correlations
• Pros and cons and pitfalls of IHC and FISH in the determination of HER2 status, and accepted practice for HER2 status determination

Friday, March 30, 2007

Back to top